Form 4: Corcept Therapeutics Executive Sean Maduck Reports Stock Transactions
SEC Form 4 Filing
Sean Maduck, President of Corcept Endocrinology, reports the acquisition and disposal of Corcept Therapeutics stock and derivative securities on February 3, 2025.
Summary
- On February 3, 2025, Sean Maduck, President of Corcept Endocrinology, reported transactions involving Corcept Therapeutics Inc. [CORT] stock.
- Maduck acquired 11,986 shares at $3.88 and 8,014 shares at $5.05 through the exercise of stock options.
- He also disposed of 20,000 shares at $66.92.
- Following these transactions, Maduck directly owns 85,318 shares of common stock and indirectly owns 10,000 shares through Duckhill Capital, LLC and 10,000 shares through Sean and Molly Maduck Living Trust.
- He also holds options to buy 10,000 + 141,986 shares of common stock.
Sentiment
Score: 5
Explanation: This is a neutral report of stock transactions. The sentiment is neither positive nor negative as it simply reflects the buying and selling activity of an executive.
Industry Context
This filing is a routine disclosure of insider trading activity, which is common for executives of publicly traded companies. It provides transparency into the trading activities of company insiders.
Stakeholder Impact
- The transactions may have a minor impact on shareholders as they provide insight into the executive's perspective on the company's stock value.
Key Dates
| Date | Description |
|---|---|
| March 1, 2024 | Grant date of restricted stock awards, 636 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer |
| September 3, 2024 | Grant date of restricted stock awards, 458 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer |
| December 2, 2024 | Grant date of restricted stock awards, 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer |
| February 3, 2025 | Date of stock and options transactions. |
| February 5, 2025 | Date of Form 4 filing. |
| February 26, 2026 | Expiration date of stock options (right to buy) at $3.88 |
| May 02, 2026 | Expiration date of stock options (right to buy) at $5.05 |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.